Replies to post #6710 on Fibrocell Science Inc (FCSC)

[CHM_760]

I am still holding shares for the long term, but not "loaded" until I can better understand the future revenue prospects.

The RDEB indication only has a "less than 2,000" US patient population. There must be something more out there to interest RJK; perhaps its the Scleroderma indication? Or just proof of concept, which might open other doors in the future.